[go: up one dir, main page]

DK2718326T3 - Antistoffer mod g-csfr og anvendelser deraf - Google Patents

Antistoffer mod g-csfr og anvendelser deraf Download PDF

Info

Publication number
DK2718326T3
DK2718326T3 DK12800867.9T DK12800867T DK2718326T3 DK 2718326 T3 DK2718326 T3 DK 2718326T3 DK 12800867 T DK12800867 T DK 12800867T DK 2718326 T3 DK2718326 T3 DK 2718326T3
Authority
DK
Denmark
Prior art keywords
csfr
antibodies
Prior art date
Application number
DK12800867.9T
Other languages
English (en)
Inventor
Andrew Donald Nash
Arna Elizabeth Andrews
Kirsten Mae Edwards
Matthew Philip Hardy
Con Panousis
Felicity Meredith Dunlop
Manuel Baca
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47353852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2718326(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of DK2718326T3 publication Critical patent/DK2718326T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK12800867.9T 2011-06-13 2012-06-13 Antistoffer mod g-csfr og anvendelser deraf DK2718326T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496351P 2011-06-13 2011-06-13
PCT/AU2012/000675 WO2012171057A1 (en) 2011-06-13 2012-06-13 Antibodies against g-csfr and uses thereof

Publications (1)

Publication Number Publication Date
DK2718326T3 true DK2718326T3 (da) 2020-10-26

Family

ID=47353852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12800867.9T DK2718326T3 (da) 2011-06-13 2012-06-13 Antistoffer mod g-csfr og anvendelser deraf

Country Status (15)

Country Link
US (6) US9193793B2 (da)
EP (1) EP2718326B1 (da)
JP (1) JP6187777B2 (da)
KR (1) KR101822702B1 (da)
CN (1) CN103649123B (da)
AU (1) AU2012269720B2 (da)
BR (1) BR112013031943B1 (da)
CA (1) CA2838246C (da)
DK (1) DK2718326T3 (da)
ES (1) ES2828482T3 (da)
IL (1) IL229468B (da)
MX (1) MX343580B (da)
RU (1) RU2605595C2 (da)
SG (1) SG195043A1 (da)
WO (1) WO2012171057A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
JP7046173B2 (ja) * 2017-10-11 2022-04-01 エランコ・ユーエス・インコーポレイテッド ブタｇ－ｃｓｆ変異体とその使用
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血－再灌流障害の治療又は予防方法
WO2019178645A1 (en) * 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2020113270A1 (en) * 2018-12-04 2020-06-11 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
WO2020248024A1 (en) * 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof
EP4041760A4 (en) * 2019-10-08 2023-10-11 Zymeworks BC Inc. MODIFIED EXTRACELLULAR DOMAIN OF GRANULOCYTE COLONY STIMULATION FACTOR RECEPTOR (G-CSFR) AND CYTOKINES BINDING THEREWITH
JP2023533658A (ja) * 2020-06-04 2023-08-04 シーエスエル イノベーション プロプライアタリー リミティド 急性呼吸窮迫症候群を治療又は予防する方法
AU2021399879A1 (en) * 2020-12-16 2023-06-22 CSL Innovation Pty Ltd Protein formulations and uses thereof
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
RU2198931C2 (ru) 1990-06-11 2003-02-20 Нексстар Фармасьютикалс Инк. Способ идентификации лигандов, способ получения антитела, способ отбора нуклеиновой кислоты, способ получения смеси нуклеиновых кислот, смесь нуклеиновых кислот, не встречающийся в природе нуклеиново-кислотный лиганд
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
AUPM375194A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PL343064A1 (en) 1998-03-20 2001-07-30 Benitec Australia Ltd Control of gene expression
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
CN1810292A (zh) 1998-05-06 2006-08-02 基因技术股份有限公司 用离子交换层析纯化蛋白质
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
AUPR544401A0 (en) 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
AU2005250055B2 (en) 2004-06-02 2008-09-11 Adalta Pty Ltd Binding moieties based on shark IgNAR domains
WO2006033386A1 (ja) 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
JP2009542197A (ja) * 2006-07-06 2009-12-03 メルク セローノ ソシエテ アノニム Ｃｓｆ３ｒポリペプチド及びそれらの使用
ES2506065T3 (es) * 2006-08-11 2014-10-13 Csl Limited Tratamiento de estados patológicos pulmonares
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
CA2745460C (en) 2008-12-19 2021-07-13 Macrogenics, Inc. Covalent diabodies and uses thereof
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
DK2477656T3 (da) * 2009-09-15 2017-06-26 Csl Ltd Behandling af neurologiske tilstande
US8968731B2 (en) 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN104610454A (zh) 2010-02-16 2015-05-13 米迪缪尼有限公司 Hsa相关组合物及使用方法
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
WO2011123745A2 (en) 2010-04-02 2011-10-06 Opko Curna Llc Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
CA2815237C (en) 2010-10-27 2018-10-09 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
AU2011359378A1 (en) 2011-02-15 2013-10-03 Medimmune, Llc HSA-related compositions and methods of use
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US20160052993A1 (en) 2013-05-03 2016-02-25 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
ES2881303T3 (es) 2014-11-17 2021-11-29 Csl Ltd Método para el tratamiento o prevención del accidente cerebrovascular
JP7065786B2 (ja) 2016-04-21 2022-05-12 シーエスエル リミティド 肝病態を治療又は予防する方法
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血－再灌流障害の治療又は予防方法
KR20190073917A (ko) 2017-12-19 2019-06-27 포항공과대학교 산학협력단 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
AU2019377456A1 (en) 2018-11-07 2021-05-27 Merck Sharp & Dohme Llc Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
WO2020113270A1 (en) 2018-12-04 2020-06-11 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
WO2020248024A1 (en) 2019-06-12 2020-12-17 CSL Innovation Pty Ltd Soluble complement receptor type 1 variant conjugates and uses thereof

Also Published As

Publication number Publication date
JP6187777B2 (ja) 2017-08-30
ES2828482T3 (es) 2021-05-26
US20120321630A1 (en) 2012-12-20
MX343580B (es) 2016-11-10
US20250051462A1 (en) 2025-02-13
US20190055313A1 (en) 2019-02-21
IL229468A0 (en) 2014-01-30
KR101822702B1 (ko) 2018-01-26
AU2012269720B2 (en) 2015-01-22
RU2014100642A (ru) 2015-07-20
MX2013014711A (es) 2014-09-01
WO2012171057A1 (en) 2012-12-20
NZ617725A (en) 2015-02-27
US20210009701A1 (en) 2021-01-14
EP2718326B1 (en) 2020-08-19
AU2012269720A1 (en) 2013-03-21
CA2838246A1 (en) 2012-12-20
KR20140041717A (ko) 2014-04-04
BR112013031943A2 (pt) 2016-11-22
US20170226214A1 (en) 2017-08-10
BR112013031943B1 (pt) 2021-10-13
RU2605595C2 (ru) 2016-12-20
CA2838246C (en) 2018-07-10
JP2014519517A (ja) 2014-08-14
US9193793B2 (en) 2015-11-24
SG195043A1 (en) 2013-12-30
EP2718326A4 (en) 2015-07-08
CN103649123A (zh) 2014-03-19
EP2718326A1 (en) 2014-04-16
US20160031998A1 (en) 2016-02-04
IL229468B (en) 2021-05-31
US12071484B2 (en) 2024-08-27
CN103649123B (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
DK2718326T3 (da) Antistoffer mod g-csfr og anvendelser deraf
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK3495392T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
EP2735594A4 (en) ADHESIVE
HUE056313T2 (hu) Anti-DLL3 antitest
PL2731677T3 (pl) Przeciwciała wiążące się z OX40 i ich zastosowania
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
IL231777B (en) Antibodies against tl1a and uses thereof
BR112012030311A2 (pt) anticorpo
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
BR112012017441A2 (pt) compostos e métodos
EP2743171A4 (en) LIQUID NATURAL GAS VEHICLES
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK2906597T3 (da) Antistoffer mod beta-amyloid
CO6791565A2 (es) Anticuerpos anti-notch1
EP2733327A4 (en) TURBO
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
HUE043576T2 (hu) Antitestek notum pektinacetilészterázhoz